No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study

Br J Dermatol. 2022 Apr;186(4):746-748. doi: 10.1111/bjd.20941. Epub 2022 Jan 23.

Authors

Zarqa Ali¹, Alexander Egeberg¹, Jacob P Thyssen¹, Jennifer Astrup Sørensen¹, Christian Vestergaard², Simon Francis Thomsen^{1

3}

Affiliations

¹ Department of Dermato-Venereology and Wound Healing Centre, Copenhagen University Hospital Bispebjerg, Denmark.
² Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark.
³ Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

PMID: 34878656
DOI: 10.1111/bjd.20941

No abstract available

Publication types

Letter

MeSH terms

Anti-Asthmatic Agents*
Cohort Studies
Humans
Neoplasms* / chemically induced
Neoplasms* / epidemiology
Omalizumab / adverse effects
Registries
Treatment Outcome

Substances

Anti-Asthmatic Agents
Omalizumab